Related Experiment Videos
Cost-effectiveness results from the US Carvedilol Heart Failure Trials Program
M Vera-Llonch1, J Menzin, R E Richner
1Policy Analysis Inc., Brookline, MA 02445-7629, USA.
The Annals of Pharmacotherapy
|August 4, 2001
Summary
Carvedilol, a heart failure treatment, was found to be cost-saving and reduce mortality in clinical trials. This beta-blocker therapy may decrease healthcare costs while improving survival rates for heart failure patients.
Area of Science:
- Cardiovascular Medicine
- Health Economics
Background:
- Heart failure (HF) is a significant public health concern associated with high mortality and healthcare costs.
- Carvedilol is an established beta-blocker approved for HF treatment in the US.
Purpose of the Study:
- To evaluate the cost-effectiveness of carvedilol in patients with heart failure.
- To assess the economic impact of carvedilol therapy alongside its mortality benefits.
Main Methods:
- Economic evaluation conducted alongside the US Carvedilol Heart Failure Trials Program.
- Analysis of four randomized, double-blind, placebo-controlled clinical trials with a mean follow-up of 6.5 months.
- Calculation of cost per death averted, considering therapy costs and cardiovascular-related inpatient care.
Main Results:
- Carvedilol therapy was associated with lower mean estimated costs of cardiovascular-related inpatient care ($1912 vs. $4463).
- Mortality was lower in the carvedilol group, resulting in a negative cost per death averted.
- High probability (0.98) of carvedilol increasing survival and decreasing care costs over 6.5 months.
Conclusions:
- Carvedilol significantly reduces mortality in patients with heart failure.
- Carvedilol therapy demonstrates potential cost-saving benefits over a six-month period.
- The findings support carvedilol as an economically favorable treatment option for heart failure.